Evan David Seigerman
Stock Analyst at BMO Capital
(3.38)
# 1,000
Out of 5,090 analysts
54
Total ratings
51.06%
Success rate
4.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $722.57 | +17.64% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $332.27 | +11.96% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $48.14 | -4.45% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $10.50 | +4.76% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $226.98 | +5.74% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $20.70 | +25.63% | 2 | Jun 12, 2025 | |
| MRUS Merus | Maintains: Outperform | $96 → $110 | $96.22 | +14.32% | 1 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $27.34 | +2.41% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $12.84 | -22.12% | 1 | May 5, 2025 | |
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $99.99 | -3.99% | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $112 | $93.04 | +20.38% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $35.80 | +179.33% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $26.02 | +38.38% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $5.24 | -42.75% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $1,007.75 | -60.70% | 1 | Sep 6, 2022 |
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $722.57
Upside: +17.64%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $332.27
Upside: +11.96%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $48.14
Upside: -4.45%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $10.50
Upside: +4.76%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $226.98
Upside: +5.74%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $20.70
Upside: +25.63%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $96.22
Upside: +14.32%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $27.34
Upside: +2.41%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $12.84
Upside: -22.12%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $99.99
Upside: -3.99%
Nov 5, 2024
Maintains: Outperform
Price Target: $70 → $112
Current: $93.04
Upside: +20.38%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $35.80
Upside: +179.33%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $26.02
Upside: +38.38%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.24
Upside: -42.75%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $1,007.75
Upside: -60.70%